Most Innovative European Biotech SME : Addex Pharmaceutical wins the EuropaBio Award 2010
Date: 05/01/2011
This new award acknowledges the outstanding contribution made by Biotech SMEs towards developing a smart, sustainable and inclusive EU economy for 2020 by providing solutions to some of society’s biggest challenges for the future. It has been presented at this year’s EuropaBio Biotechnology Benefits for Innovation event on 9 December in Brussels which brought together a high-level audience of over 200 Biotech company CEOs, EU decision makers, journalists, VCs and other stakeholders.
EuropaBio’s first ever Most Innovative European Biotech SME Award has attracted an outstanding array of applications from 32 companies across 12 countries representing all sectors of the biotech industry.
Addex Pharmaceuticals triumphed as winners over stiff competition from 31 other biotech companies demonstrating cutting edge innovation in biotechnology from across the healthcare, agricultural and industrial sectors.
The Geneva-based company, which was founded in 2002, was selected as the over all winner by a high-level judging panel from a final shortlist of five companies which also included AMSilk, KeyGene, Prosensa and TiGenix.
Addex Pharmaceuticals were honoured for their discoveries and developments in the field of allosteric modulators for human health focused on validated therapeutic targets for diseases of the central nervous system, metabolic disorders and inflammation.
The company has demonstrated the potential of the technology by advancing products to Phase II clinical testing and partnering with two major pharmaceutical companies. In addition, Addex recently received a grant from the Michael J. Fox Foundation to support Phase II clinical testing of its lead product for Parkinson’s disease. Based upon its technology, which facilitates drug discovery for challenging therapeutic targets, Addex is developing products that may address some of the most important diseases such as Alzheimer’s, multiple sclerosis, type II diabetes, rheumatoid arthritis, depression and sleep disorders.
For further information please see the respective document or visit http://www.europabio.org/
< back to the list